| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KRT8 |
| Uniprot No | P05787 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-483aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSIRVTQKSYKVSTSGPRAFSSRSYTS GPGSRISSSSFSRVGSSNFRGGLGGGYGGASGMGGITAVTVNQSLLSPLV LEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLETKWSLLQ QQKTARSNMDNMFESYINNLRRQLETLGQEKLKLEAELGNMQGLVEDFKN KYEDEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQL YEEEIRELQSQISDTSVVLSMDNSRSLDMDSIIAEVKAQYEDIANRSRAE AESMYQIKYEELQSLAGKHGDDLRRTKTEISEMNRNISRLQAEIEGLKGQ RASLEAAIADAEQRGELAIKDANAKLSELEAALQRAKQDMARQLREYQEL MNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYAGGLSSAY GGLTSPGLSYSLGSSFGSGAGSSSFSRTSSSRAVVVKKIETRDGKLVSES SDVLPK |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KRT8重组蛋白的模拟参考文献示例(基于已有知识框架构造，非真实文献)：
---
1. **文献名称**: *Expression and purification of recombinant human keratin 8 in Escherichia coli*
**作者**: Smith J, et al.
**摘要**: 研究报道了通过大肠杆菌表达系统高效生产重组人KRT8蛋白的方法，优化了诱导条件和纯化步骤(使用His标签亲和层析)，并验证了重组蛋白的二级结构稳定性，为后续功能研究提供材料基础。
2. **文献名称**: *Recombinant KRT8 phosphorylation modulates epithelial cell stress response*
**作者**: Lee H, et al.
**摘要**: 通过体外磷酸化修饰重组KRT8蛋白，发现其在热休克和氧化应激条件下通过调节细胞骨架重塑增强上皮细胞存活能力，提示KRT8磷酸化在细胞应激信号通路中的关键作用。
3. **文献名称**: *KRT8 recombinant protein as a potential biomarker in liver fibrosis*
**作者**: Wang Y, et al.
**摘要**: 利用重组KRT8蛋白制备特异性抗体，发现肝纤维化患者血清中KRT8片段水平显著升高，提示重组KRT8可用于开发疾病诊断工具或作为治疗靶点。
4. **文献名称**: *Functional analysis of KRT8 mutations using recombinant proteins in vitro*
**作者**: Garcia R, et al.
**摘要**: 通过构建KRT8点突变重组蛋白(如G62C)，对比野生型发现突变体导致中间丝组装异常，解释了特定突变引发消化系统上皮脆性疾病的分子机制。
---
**注**：以上文献为模拟示例，实际研究需通过学术数据库(如PubMed、Web of Science)检索真实发表文章。建议使用关键词“recombinant KRT8”或“keratin 8 expression”进行精准查询。
Keratin 8 (KRT8), a member of the type II keratin family, is an intermediate filament protein primarily expressed in simple epithelial tissues, including the liver, pancreas, and gastrointestinal tract. As part of the cytoskeleton, it forms heteropolymers with type I keratins (e.g., KRT18/KRT19) to maintain cell mechanical integrity, regulate signaling pathways, and protect against stress-induced damage. Its structure features a central α-helical rod domain flanked by non-helical head and tail regions, critical for filament assembly and protein interactions.
Recombinant KRT8 protein is produced using engineered expression systems (e.g., E. coli, mammalian cells) to achieve high purity and bioactivity for research applications. Studies highlight its role in disease mechanisms: KRT8 mutations or dysregulation are linked to liver disorders (e.g., cryptogenic cirrhosis), inflammatory bowel disease, and cancer progression. Phosphorylation of KRT8 during apoptosis or cellular stress modulates its interaction with chaperones like HSP70. influencing cell survival. In cancers, elevated KRT8 expression correlates with metastasis and drug resistance, making it a potential diagnostic marker or therapeutic target.
Researchers use recombinant KRT8 to investigate epithelial-mesenchymal transition (EMT), screen drugs targeting keratin networks, and develop antibodies for pathological diagnosis. Its application extends to 3D cell culture models to study epithelial barrier function. Despite its physiological importance, KRT8's dynamic post-translational modifications and tissue-specific roles warrant further exploration. Recombinant variants, including phospho-mimetic mutants, are instrumental in dissecting these mechanisms under controlled experimental conditions.
×
